资讯库
更紧凑的生命科学资讯库。
先搜索，再按来源或主题继续收窄。
诺和诺德股价因阿尔茨海默症药物semaglutide两项试验失败而暴跌8%
Novo Nordisk has come up short in two phase 3 trials of semaglutide as a treatment for Alzheimer’s disease. But perhaps the larger story associated with the unsurprisin...
先搜索，再按来源或主题继续收窄。
Novo Nordisk has come up short in two phase 3 trials of semaglutide as a treatment for Alzheimer’s disease. But perhaps the larger story associated with the unsurprisin...